CD274 and neoplasm: Several potential biomarkers have been studied to predict the response to immunotherapy in aHCC, including immune cell infiltration, programmed death-ligand 1 (PD-L1) expression, tumour mutational burden (TMB), and microsatellite instability (MSI).